// App-Quantinova.ai

1375 : Investigating synergy between CHK1 and PARP inhibitors in BRCA2 mutant and restored cells

Researchers

Presenter

  • Hannah L. Smith

Principal Investigators

  • Lisa Prendergast

  • Nicola J. Curtin

Medical Centers

  • Newcastle University, Newcastle upon Tyne, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Breast cancer type 2 susceptibility protein

  • Checkpoint kinase 1

  • RAD51 Recombinase

  • WEE1 G2 Checkpoint Kinase

  • Hormone receptor

Drug/Treatment

  • Rucaparib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved